These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11974557)

  • 1. Estrogen and colon cancer: current issues.
    al-Azzawi F; Wahab M
    Climacteric; 2002 Mar; 5(1):3-14. PubMed ID: 11974557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA; Blake JM; Crosignani PG
    Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term use of progestogens: colon adenoma and colon carcinoma.
    Schindler AE
    Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():42-4. PubMed ID: 17943538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective modulation of postmenopausal women: cutting the Gordian knot of hormone replacement therapy with breast carcinoma.
    Diamanti-Kandarakis E; Sykiotis GP; Papavassiliou AG
    Cancer; 2003 Jan; 97(1):12-20. PubMed ID: 12491500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Review of risk factors for breast cancer--what's new?].
    Haimov-Kochman R; Lavy Y; Hochner-Celinkier D
    Harefuah; 2002 Aug; 141(8):702-8, 761. PubMed ID: 12222134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women.
    Schwartz AG; Wenzlaff AS; Prysak GM; Murphy V; Cote ML; Brooks SC; Skafar DF; Lonardo F
    J Clin Oncol; 2007 Dec; 25(36):5785-92. PubMed ID: 18089876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario.
    Carruba G
    J Cell Biochem; 2007 Nov; 102(4):899-911. PubMed ID: 17786930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer.
    Alvarez-Vasquez RB; Axelrod D; Frenkel K; Newman MC; Sepkovic DW; Bradlow HL; Zumoff B
    Horm Metab Res; 2003 Jun; 35(6):358-61. PubMed ID: 12920658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
    Pasqualini JR; Chetrite GS
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.
    Quick SK; Shields PG; Nie J; Platek ME; McCann SE; Hutson AD; Trevisan M; Vito D; Modali R; Lehman TA; Seddon M; Edge SB; Marian C; Muti P; Freudenheim JL
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1082-7. PubMed ID: 18483329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients.
    Altundag O; Altundag K; Gunduz M
    Med Hypotheses; 2004; 63(4):684-7. PubMed ID: 15325017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
    Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M; Koera K; Nagata H; Nakano H
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
    Kerlikowske K; Miglioretti DL; Ballard-Barbash R; Weaver DL; Buist DS; Barlow WE; Cutter G; Geller BM; Yankaskas B; Taplin SH; Carney PA
    J Clin Oncol; 2003 Dec; 21(23):4314-21. PubMed ID: 14645420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study.
    Wellejus A; Olsen A; Tjonneland A; Thomsen BL; Overvad K; Loft S
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2137-42. PubMed ID: 16172222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
    Koledova VV; Khalil RA
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
    Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
    Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.